Neurosteer

About:

Neurosteer® offers a wearable device for the early detection and treatment of a variety of neurological disorders, including Alzheimer’s.

Website: https://www.neurosteer.com

Twitter/X: neurosteer

Top Investors: EASME - EU Executive Agency for SMEs, Arkady Volozh

Description:

Neurosteer® has developed a solution for the early detection and more effective treatment of a variety of neurological disorders. It consists of a medical-grade wearable device and cloud-based system that provides real-time monitoring and assessment of brain activity. The company’s current focus is on delivering objective biomarkers that identify the early onset of Parkinson’s, Alzheimer’s, dementia and epilepsy. Neurosteer uses an adhesive forehead strip connected to a pocket-sized device that wirelessly transmits sensor data to the cloud for proprietary signal processing. Advanced algorithms then decompose the single EEG channel into 100+ individual components for real-time analysis and display on a Web-based dashboard. The result is more affordable screening, continuous patient monitoring, and optimized neurostimulation and drug selection, leading to improved neurological treatment and outcome of clinical trials.

Total Funding Amount:

$6.58M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

New York, New York, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)neurosteer.com

Founders:

Nathan Intrator

Number of Employees:

11-50

Last Funding Date:

2019-06-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai